Companies › Aurion Biotech
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cryopreserved AURN001 Corneal endothelial cell therapy with Rho kinase inhibitor | ROCK1, ROCK2 | Phase 3 | Corneal Edema | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06630169 | Cryopreserved AURN001 | Phase 2 | Corneal Edema | Ophthalmology | Oct 2025 |
| NCT07368959 | Cryopreserved AURN001 | Phase 3 | Corneal Edema | Ophthalmology | Jun 2027 |
Woolsey Pharmaceuticals Sanofi Chia Tai Tianqing Pharmaceutical Group
Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Smilebiotek Zhuhai Beletalent (Zhuhai) Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.